Literature DB >> 18046501

Up-regulation of vimentin expression in low-density malignant glioma cells as immediate and late effects under irradiation and temozolomide treatment.

Daniela Trog1, Kristina Yeghiazaryan, Hans H Schild, Olga Golubnitschaja.   

Abstract

Nervous system tumors are one of the leading causes of cancer related death. Specific mechanisms facilitating the invasive behavior of gliomas remain obscure. Advanced simulation models of the in vivo response to therapy conditions should potentially improve malignant glioma treatment. Expressional profiling of vimentin--one of reliable pro-invasive tumor makers--in those simulation models was the goal of this study, in order to estimate a pro-invasive response of surviving malignant glioma cells under clinically relevant therapeutic conditions. Human U87-MG malignant glioma cells were used. These cells are characterized by the wild p53-phenotype, which is relevant for the majority of primary malignant glioblastomas. Experimental design foresaw the cells to undergo either irradiation or chemo-treatment with temozolomide alone, or combined treatment. Expression profiling of vimentin was performed by quantitative "Real-Time"-PCR under all treatment conditions simulating diverse tumor regions. Here we demonstrated that vimentin expression patterns in human malignant glioma cells strongly depend on cellular density, algorithms of drug delivery and chemo/radio treatment. Substantial differences were recognized between immediate and late therapy effects. Significant increase in vimentin expression levels was detected particularly in low-density cell cultures under durable treatment with constant concentration levels of temezolomide. Simulation of variable intratumoral regional conditions (central intratumoral regions vs. disseminated malignant cells in peripheral regions) demonstrated differential response of vimentin expression in malignant glioma cell cultures treated under clinically relevant conditions. Slight ebbing of expression levels as late effects of the treatment in confluent cultures may correspond to necrotic processes clinically observed in central intratumoral regions. Contrary, in disseminated malignant cells of peripheral regions therapy resulted in vimentin-inducing effects. This is in agreement with the clinical observations of an increased aggressiveness and malignancy grade of post-operatively chemo/radio-treated malignant gliomas.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18046501     DOI: 10.1007/s00726-007-0007-4

Source DB:  PubMed          Journal:  Amino Acids        ISSN: 0939-4451            Impact factor:   3.520


  10 in total

Review 1.  Vimentin in cancer and its potential as a molecular target for cancer therapy.

Authors:  Arun Satelli; Shulin Li
Journal:  Cell Mol Life Sci       Date:  2011-06-03       Impact factor: 9.261

2.  TR4 nuclear receptor promotes clear cell renal cell carcinoma (ccRCC) vasculogenic mimicry (VM) formation and metastasis via altering the miR490-3p/vimentin signals.

Authors:  Jian Bai; Shuyuan Yeh; Xiaofu Qiu; Linyi Hu; Jun Zeng; Yangke Cai; Li Zuo; Gonghui Li; Guosheng Yang; Chawnshang Chang
Journal:  Oncogene       Date:  2018-07-04       Impact factor: 9.867

3.  Quantitative Proteomics Analysis Reveals Novel Insights into Mechanisms of Action of Long Noncoding RNA Hox Transcript Antisense Intergenic RNA (HOTAIR) in HeLa Cells.

Authors:  Peng Zheng; Qian Xiong; Ying Wu; Ying Chen; Zhuo Chen; Joy Fleming; Ding Gao; Lijun Bi; Feng Ge
Journal:  Mol Cell Proteomics       Date:  2015-03-11       Impact factor: 5.911

4.  Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines.

Authors:  Stella Sun; T S Wong; X Q Zhang; Jenny K S Pu; Nikki P Lee; Philip J R Day; Gloria K B Ng; W M Lui; Gilberto K K Leung
Journal:  J Neurooncol       Date:  2011-10-07       Impact factor: 4.130

5.  Differentially expressed proteins in glioblastoma multiforme identified with a nanobody-based anti-proteome approach and confirmed by OncoFinder as possible tumor-class predictive biomarker candidates.

Authors:  Ivana Jovčevska; Neja Zupanec; Žiga Urlep; Andrej Vranič; Boštjan Matos; Clara Limbaeck Stokin; Serge Muyldermans; Michael P Myers; Anton A Buzdin; Ivan Petrov; Radovan Komel
Journal:  Oncotarget       Date:  2017-07-04

6.  Glioblastoma Multiforme Selective Nanomedicines for Improved Anti-Cancer Treatments.

Authors:  Jason Thomas Duskey; Arianna Rinaldi; Ilaria Ottonelli; Riccardo Caraffi; Chiara Alessia De Benedictis; Ann Katrin Sauer; Giovanni Tosi; Maria Angela Vandelli; Barbara Ruozi; Andreas Martin Grabrucker
Journal:  Pharmaceutics       Date:  2022-07-12       Impact factor: 6.525

7.  Increased phosphorylation of vimentin in noninfiltrative meningiomas.

Authors:  Ali Bouamrani; Claire Ramus; Emmanuel Gay; Laurent Pelletier; Myriam Cubizolles; Sabine Brugière; Didier Wion; François Berger; Jean-Paul Issartel
Journal:  PLoS One       Date:  2010-02-16       Impact factor: 3.240

8.  Polymerase I and transcript release factor acts as an essential modulator of glioblastoma chemoresistance.

Authors:  Xin Wang; Tianzhu Liu; Yifeng Bai; Hongzhan Liao; Shengcong Qiu; Zhenhua Chang; Yanting Liu; Xiaohui Yan; Hongbo Guo
Journal:  PLoS One       Date:  2014-04-18       Impact factor: 3.240

Review 9.  The Expressions and Mechanisms of Sarcomeric Proteins in Cancers.

Authors:  Xiaojing Yang; Hanru Ren; Xiaomao Guo; Chaosu Hu; Jie Fu
Journal:  Dis Markers       Date:  2020-06-30       Impact factor: 3.434

Review 10.  Vimentin Diversity in Health and Disease.

Authors:  Frida Danielsson; McKenzie Kirsten Peterson; Helena Caldeira Araújo; Franziska Lautenschläger; Annica Karin Britt Gad
Journal:  Cells       Date:  2018-09-21       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.